Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Switching rate from intravenous to subcutaneous vedolizumab in managing inflammatory bowel diseases is lower than expected
Publication Year: 2025 Source: Minerva Gastroenterol (Torino) PMID: 39471042 DOI: 10.23736/S2724-5985.24.03712-4
BACKGROUND: It is known that the subcutaneous (SC) route administration of biologic drugs has several potential benefits for patient and the healthcare system. Since few real-world data are available yet about the rate of transition from intravenous (IV) to SC Vedolizumab (VDZ) in the Italian population, we assessed this rate …
Discovery and Total Synthesis of Anhydrotuberosin as a STING Antagonist for Treating Autoimmune Diseases
Publication Year: 2025 Source: Angew Chem Int Ed Engl PMID: 39471366 DOI: 10.1002/anie.202407641
Excessive activation of the stimulator of the interferon gene (STING) pathway has been identified as a significant contributor to various autoimmune diseases, such as STING-associated vasculopathy with infantile-onset (SAVI) and inflammatory bowel disease (IBD). However, discovering effective STING antagonists for treating STING-mediated autoimmune disorders remains challenging. Herein, we identified the …
Refining metabolic health assessment in inflammatory bowel disease risk prediction
Publication Year: 2025 Source: Eur J Intern Med PMID: 39472189
No Abstract
Intestinal vascular diseases misdiagnosed as Crohn disease: analysis of 13 cases
Publication Year: 2025 Source: Pathology PMID: 39472272
No Abstract
The impact of anxiety and depression on quality of life in a cohort of inflammatory bowel disease patients from Northeastern of Brazil
Publication Year: 2025 Source: Gastroenterol Hepatol PMID: 39477185 DOI: 10.1016/j.gastrohep.2024.502283
OBJECTIVE: This study aims to assess whether the association between chronic pathologies and depressive and/or anxious disorders is high, resulting in a reduction in the patient's quality of life. PATIENTS AND METHODS: This is a prospective cross-sectional study with a descriptive and analytical design. Sociodemographic data and lifestyle habits were …
Comparative Effectiveness of Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis: A Propensity-Matched Cohort Analysis
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 39478367
INTRODUCTION: There is limited real-world evidence comparing the effectiveness of ozanimod to vedolizumab as first-line advanced therapies in patients with ulcerative colitis (UC). METHODS: We conducted a retrospective cohort study using TriNetX, a multi-institutional US database in adults with UC who were initiated on ozanimod compared to vedolizumab between January …
When and What to Test for Diarrhea: Focus on Stool Testing
Publication Year: 2025 Source: Am J Gastroenterol PMID: 39480027
No Abstract
Gut microbiome-targeted therapies as adjuvant treatments in inflammatory bowel diseases: a systematic review and network meta-analysis
Publication Year: 2025 Source: J Gastroenterol Hepatol PMID: 39482823 DOI: 10.1111/jgh.16795
BACKGROUND AND AIM: Gut microbiome-targeted therapies (MTTs), including prebiotics, probiotics, synbiotics, and fecal microbiota transplantation (FMT), have been widely used in inflammatory bowel diseases (IBD), but the best MTTs has not yet been confirmed. We performed a network meta-analysis (NMA) to examine this in ulcerative colitis (UC) and Crohn's disease …
Self-Management and Relationships: Perspectives of Young Adults With Chronic Conditions and Their Peers
Publication Year: 2025 Source: Qual Health Res PMID: 39484710
No Abstract
Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies
Publication Year: 2025 Source: J Crohns Colitis PMID: 39485390
BACKGROUND AND AIMS: Normalization of high-sensitivity C-reactive protein (hs-CRP) and fecal calprotectin (FCP) are suggested as intermediate treatment targets for Crohn's disease (CD). This analysis evaluates achievement of biomarker normalization and the relationship between improvements in biomarker concentrations and clinical and endoscopic outcomes among patients treated with risankizumab. METHODS: This …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide